Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
NCT ID: NCT05032898
Last Updated: 2021-09-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
1500 participants
OBSERVATIONAL
2021-09-30
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study
NCT02657525
Predicting Risk Factors for Exacerbation of Chronic Obstructive Pulmonary Disease
NCT03450603
Early COPD for China Pulmonary Health Study Stage II
NCT05028985
Treatment in Patients Hospitalized With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT02219360
Biomarker of Acute Exacerbation of COPD
NCT04963244
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Eligibility Criteria: Details are shown in the Eligibility Criteria part.
Procedures and Measurements: At admission, each eligible subject will be given an in-depth interview to collect the demographics, smoking history, medical history, management of disease during stable period, etc. During hospitalization, treatment and auxiliary examination results including laboratory and lung function tests will be recorded if available. To ensure the quality and uniformity of spirometry data, training on performing spirometry will be provided to each study site by professional doctors from central site. At discharge, physicians will record the discharge diagnoses and clinical outcomes including death, intensive care unit admission, chronic obstructive pulmonary disease assessment test (CAT) score and total direct cost for each participant. During follow-ups, clinical outcomes including death and exacerbation events, change of medication, new-developed complications, auxiliary examination results, and economic burden will be collected.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* hospitalized with main diagnosis of acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Exclusion Criteria
* participating in clinical trials or intervention studies of drugs
* diagnosed as active pulmonary tuberculosis, or acute left heart failure
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
China-Japan Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chen Wang
Principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chen Wang, Doctor
Role: STUDY_CHAIR
Institue of Basic Medical Sciences Chinese Academy of Medical Sciences
Ting Yang, Doctor
Role: PRINCIPAL_INVESTIGATOR
China-Japan Friendship Hospital
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AECOPD-IRS-II
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.